金吾财讯 | 有报道引述中国宜联生物公司(MediLink Therapeutics Ltd)正寻求就旗下抗体偶联药物(ADC)YL201,与一家全球制药公司达成授权协议,这将为公司最快2026年在香港上市铺路。消息指,目前的协商仍在进行当中,最终是否能够达成协议还无法确定。据悉,宜联生物总部位于苏州,于2020年7月8日成立,是一家专注于ADC(抗体偶联药物)及相关技术创新药物开发的企业,并且在上海和波士顿设置了研发中心。YL201是一款靶向B7H3的ADC药物。目前,YL201正在全球范围内开展针对多种实体瘤的探索性研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.